Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2005

01-10-2005 | Review

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening

Author: Sue Moss

Published in: Breast Cancer Research | Issue 5/2005

Login to get access

Abstract

Data from randomised controlled trials of mammographic screening can be used to determine the extent of any overdiagnosis, as soon as either a time equivalent to the lead-time has elapsed after the final screen, or the control arm has been offered screening. This paper reviews those randomised trials for which breast cancer incidence data are available. In recent trials in which the control group has not been offered screening, an excess incidence of breast cancer remains after many years of follow-up. In those trials in which the control arm has been offered screening, although there is a possible shift from invasive to in situ disease, there is no evidence of overdiagnosis as a result of incident screens.
Appendix
Available only for authorised users
Literature
1.
Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW: Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer. 2003, 39: 1746-1754. 10.1016/S0959-8049(03)00260-0.CrossRefPubMed
2.
Vainio H, Bianchini F: Breast Cancer Screening: IARC Handbooks of Cancer Prevention. 2002, Lyon: IARC Press
3.
Shapiro S, Venet W, Strax P, Venet L, Roeser R: Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst. 1982, 69: 349-355.PubMed
4.
Shapiro S: Evidence on screening for breast cancer from a randomized trial. Cancer. 1977, 39: 2772-2782.CrossRefPubMed
5.
Tabar L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Grontoft O, Ljunquist U, Lundstrom B, Manson JC, Eklund G, et al: Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health & Welfare. Lancet. 1985, i: 829-832. 10.1016/S0140-6736(85)92204-4.CrossRef
6.
Duffy SW, Tabar L, Vitak B, Day NE, Smith RA, Chen HHT, Yen MFA: The relative contributions of screen-detected insitu and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer. 2003, 39: 1755-1760. 10.1016/S0959-8049(03)00259-4.CrossRefPubMed
7.
Bjurstam N, Bjorneld L, Warwick J, Sala E, Duffy SW, Nystrom L, Walker N, Cahlin E, Eriksson O, Hafstrom LO, et al: The Gothenburg Breast Screening Trial. Cancer. 2003, 97: 2387-2396. 10.1002/cncr.11361.CrossRefPubMed
8.
Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfusson B: Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ. 1988, 297: 943-948.CrossRefPubMedPubMedCentral
9.
Frisell J, Lidbrink E, Hellstrom L, Rutqvist L-E: Follow up after 11 years – update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Res Treat. 1997, 45: 263-270. 10.1023/A:1005872617944.CrossRefPubMed
10.
Miller AB, Baines CJ, To T, Wall C: Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J. 1992, 147: 1477-1488.
11.
Miller AB, To T, Baines CJ, Wall C: Canadian National Breast Screening Study – 2: 13-year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst. 2000, 92: 1490-1499. 10.1093/jnci/92.18.1490.CrossRefPubMed
12.
Miller AB, Baines CJ, To T, Wall C: Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J. 1992, 147: 1459-1476.
13.
Miller AB, To T, Baines CJ, Wall C: The Canadian National Breast Screening Study – 1: Breast cancer mortality after 11 to 16 years of follow-up. Ann Intern Med. 2002, 137: E-305-E-315.CrossRef
14.
Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, McDonald C, Muir BB, Prescott RJ, Shepherd SM: The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. Br J Cancer. 1994, 70: 542-548.CrossRefPubMedPubMedCentral
15.
Alexander FE, Anderson TJ, Brown HK, Forrest APM, Hepburn W, Kirkpatrick AE, Muir BB, Prescott RJ, Smith A: 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet. 1999, 353: 1903-1908. 10.1016/S0140-6736(98)07413-3.CrossRefPubMed
16.
Moss S: A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group. J Med Screen. 1999, 6: 144-148.CrossRefPubMed
17.
Moss S, Waller M, Anderson TJ, Cuckle H, (writing committee for the Trial Management Group): Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer. 2005, 92: 955-960. 10.1038/sj.bjc.6602395.CrossRefPubMedPubMedCentral
18.
The Breast Screening Frequency Trial Group: The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. Eur J Cancer. 2002, 38: 1458-1464. 10.1016/S0959-8049(01)00397-5.CrossRef
Metadata
Title
Overdiagnosis and overtreatment of breast cancer: Overdiagnosis in randomised controlled trials of breast cancer screening
Author
Sue Moss
Publication date
01-10-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1314

Other articles of this Issue 5/2005

Breast Cancer Research 5/2005 Go to the issue

Research article

A new option for early breast cancer patients previously irradiated for Hodgkin's disease: intraoperative radiotherapy with electrons (ELIOT)

Letter

CYP2D6 genotype and tamoxifen response

Research article

Strong evidence that the common variant S384F in BRCA2has no pathogenic relevance in hereditary breast cancer

Research article

Epigenetic silencing of DSC3 is a common event in human breast cancer

Research article

Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+metastatic breast cancer in mice

Research article

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits